We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
Read MoreHide Full Article
For Immediate Release
Chicago, IL –July 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include PepsiCo (PEP - Free Report) , Eli Lilly (LLY), Broadcom (AVGO - Free Report) , Biogen (BIIB - Free Report) and Marathon Petroleum (MPC - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for PepsiCo, Eli Lilly and Broadcom
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Eli Lilly and Broadcom. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
PepsiCo’s shares have decreased 7% year to date, underperforming the Zacks Soft Beverages industry, which has declined -5.1% over the same period. However, PepsiCo has surpassed the industry in the past month driven by a solid earnings trend with beat recorded in the last 10 quarters, including second-quarter 2018.
Strong performances in its international division, backed by higher revenue growth in developing and emerging markets have been aiding results. Further, the company has reported positive sales surprise in six of the last eight quarters.
The Zacks analyst thinks the company is also gaining from significant strength in the snacks business, which has mostly offset the sluggishness in beverage category. The company’s product innovations to include healthier food assortments and non-carbonated drinks in its portfolio should boost sales. However, consumers’ awareness on health and wellness, alongside new taxes on sugar-sweetened beverages and growing regulatory pressures are affecting CSD sales.
Shares of Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry year to date (+5.3% vs. -0.8%). The Zacks analyst thinks Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year.
The decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent one, in our view. However, competitive pressure on Lilly’s drugs is expected to rise this year.
Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Estimates have remained stable ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters.
Broadcom’s shares have underperformed the Zacks Electronics - Semiconductors industry over the past year, losing -16.1% vs. -8.3%. Broadcom is a premier designer, developer and global supplier of a broad range of semiconductor devices.
The Zacks analyst thinks the company is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G. Strong ties with leading OEMs across multiple target markets will help the company to gain key insights into the requirements of customers.
The company faces intensifying competition and integration risks due to frequent acquisitions. Broadcom’s leveraged balance sheet and customer concentration continue to be headwinds.
Other noteworthy reports we are featuring today include Biogen and Marathon Petroleum.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
For Immediate Release
Chicago, IL –July 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include PepsiCo (PEP - Free Report) , Eli Lilly (LLY), Broadcom (AVGO - Free Report) , Biogen (BIIB - Free Report) and Marathon Petroleum (MPC - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for PepsiCo, Eli Lilly and Broadcom
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Eli Lilly and Broadcom. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
PepsiCo’s shares have decreased 7% year to date, underperforming the Zacks Soft Beverages industry, which has declined -5.1% over the same period. However, PepsiCo has surpassed the industry in the past month driven by a solid earnings trend with beat recorded in the last 10 quarters, including second-quarter 2018.
Strong performances in its international division, backed by higher revenue growth in developing and emerging markets have been aiding results. Further, the company has reported positive sales surprise in six of the last eight quarters.
The Zacks analyst thinks the company is also gaining from significant strength in the snacks business, which has mostly offset the sluggishness in beverage category. The company’s product innovations to include healthier food assortments and non-carbonated drinks in its portfolio should boost sales. However, consumers’ awareness on health and wellness, alongside new taxes on sugar-sweetened beverages and growing regulatory pressures are affecting CSD sales.
Shares of Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry year to date (+5.3% vs. -0.8%). The Zacks analyst thinks Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year.
The decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent one, in our view. However, competitive pressure on Lilly’s drugs is expected to rise this year.
Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Estimates have remained stable ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters.
Broadcom’s shares have underperformed the Zacks Electronics - Semiconductors industry over the past year, losing -16.1% vs. -8.3%. Broadcom is a premier designer, developer and global supplier of a broad range of semiconductor devices.
The Zacks analyst thinks the company is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G. Strong ties with leading OEMs across multiple target markets will help the company to gain key insights into the requirements of customers.
The company faces intensifying competition and integration risks due to frequent acquisitions. Broadcom’s leveraged balance sheet and customer concentration continue to be headwinds.
Other noteworthy reports we are featuring today include Biogen and Marathon Petroleum.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.